AzurRx BioPharma Inc (NASDAQ:AZRX) has been assigned an average rating of “Buy” from the seven ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $7.58.
Several brokerages have recently commented on AZRX. HC Wainwright set a $3.00 target price on McEwen Mining and gave the stock a “buy” rating in a research report on Friday, May 24th. National Securities began coverage on AzurRx BioPharma in a research report on Tuesday, June 11th. They issued a “buy” rating and a $9.00 target price for the company. Finally, Maxim Group reiterated a “buy” rating and issued a $315.00 target price (up previously from $305.00) on shares of Domino’s Pizza in a research report on Wednesday, April 24th.
A number of large investors have recently added to or reduced their stakes in AZRX. 683 Capital Management LLC boosted its position in AzurRx BioPharma by 73.9% during the 4th quarter. 683 Capital Management LLC now owns 695,504 shares of the company’s stock valued at $842,000 after purchasing an additional 295,504 shares during the period. Waldron Private Wealth LLC acquired a new position in AzurRx BioPharma during the 1st quarter valued at approximately $169,000. Finally, Regentatlantic Capital LLC acquired a new position in AzurRx BioPharma during the 1st quarter valued at approximately $48,000. Institutional investors and hedge funds own 13.12% of the company’s stock.
AzurRx BioPharma (NASDAQ:AZRX) last issued its earnings results on Wednesday, May 15th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.08). As a group, sell-side analysts forecast that AzurRx BioPharma will post -0.77 EPS for the current year.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Read More: Key terms to understand channel trading
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.